Drugs Containing Excipient (Inactive Ingredient) SILICON DIOXIDE, COLLOIDAL

« Back to Dashboard

Branded drugs containing SILICON DIOXIDE, COLLOIDAL excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	ALLEGRA D 12 HOUR ALLERGY AND CONGESTION	fexofenadine hydrochloride and pseudoephedrine hydrochloride	21695-931	SILICON DIOXIDE, COLLOIDAL
Physicians Total Care Inc	TEKTURNA	aliskiren hemifumarate	54868-5772	SILICON DIOXIDE, COLLOIDAL

Generic drugs containing SILICON DIOXIDE, COLLOIDAL excipient

Company	Ingredient	NDC	Excipient
Blenheim Pharmacal Inc	diazepam	10544-161	SILICON DIOXIDE, COLLOIDAL
Rebel Distributors Corp	fexofenadine hydrochloride and pseudoephedrine hydrochloride	21695-931	SILICON DIOXIDE, COLLOIDAL
HJ Harkins Company Inc	prednisone	52959-126	SILICON DIOXIDE, COLLOIDAL

Colloidal Silicon Dioxide Excipient Market Dynamics and Financial Trajectory

Last updated: August 13, 2026

Colloidal silicon dioxide is a mature, globally supplied pharmaceutical excipient used mainly as a glidant, anti-caking agent, adsorbent, suspension aid, and processing enhancer in oral solid dosage forms. Demand is tied to tablet and capsule production rather than to a single therapeutic class. The market has durable volume growth, limited product-level pricing power, and meaningful qualification barriers once a manufacturer is approved in a drug product.

The strongest commercial position belongs to suppliers with pharmaceutical-grade manufacturing, global regulatory documentation, consistent particle-size control, and technical support. Evonik, Cabot, Wacker Chemie, and other specialty silica manufacturers compete through grade performance, supply reliability, and customer qualification rather than through conventional pharmaceutical patent exclusivity.

What is colloidal silicon dioxide used for in pharmaceuticals?

Colloidal silicon dioxide is a finely divided, amorphous form of silicon dioxide, generally identified by CAS Number 7631-86-9. It is also known as colloidal silica, fumed silica, and, in food applications, silicon dioxide or E551.

Its principal pharmaceutical functions are:

Function	Commercial purpose
Glidant	Improves powder flow during tablet compression and capsule filling
Anti-caking agent	Limits agglomeration in powders and blends
Adsorbent	Converts liquid or oily ingredients into free-flowing powders
Suspension aid	Increases viscosity and reduces sedimentation
Processing aid	Improves blend uniformity and manufacturing consistency
Carrier	Supports low-dose active ingredients or liquid formulations

The excipient is most valuable in direct-compression and high-throughput solid-dose manufacturing. It is usually used at low concentrations, which limits its revenue contribution per dosage unit but increases the importance of consistent functionality.

The United States Pharmacopeia-National Formulary and European Pharmacopoeia recognize colloidal silicon dioxide as a compendial pharmaceutical material. The U.S. Food and Drug Administration lists silicon dioxide and related forms in its Inactive Ingredient Database for approved drug products, subject to route, dosage form, and concentration limitations recorded in the database (U.S. Food and Drug Administration, n.d.-a).

How large is the colloidal silicon dioxide pharmaceutical market?

There is no authoritative public market total for pharmaceutical-grade colloidal silicon dioxide alone. Public market reports commonly combine pharmaceutical, food, cosmetics, coatings, electronics, rubber, and industrial applications. Supplier disclosures also generally aggregate colloidal silica with broader specialty silica or health-care portfolios.

The pharmaceutical segment is structurally smaller than industrial silica markets but has higher qualification value. Its economic profile is defined by:

• Low excipient content per tablet or capsule.
• High annual unit volumes.
• Long customer qualification cycles.
• Limited supplier switching after regulatory approval.
• Technical requirements that differ by dosage form and formulation.
• Price sensitivity in generic medicines.
• Higher margins for validated pharmaceutical grades than for commodity silica.

Demand growth should track global oral solid-dose volumes, generic penetration, contract manufacturing, and expansion of pharmaceutical production in India, China, Southeast Asia, and other cost-competitive regions. Growth is likely to be steady rather than rapid because colloidal silicon dioxide is an established excipient with broad substitution options.

What factors are driving demand for colloidal silicon dioxide?

Growth in oral solid dosage manufacturing

Tablets and hard capsules remain the largest application base for pharmaceutical excipients. Colloidal silicon dioxide improves flow in formulations containing poorly flowing active pharmaceutical ingredients, high-dose powders, and blends with different particle sizes or densities.

Generic drug manufacturers use the material to improve process robustness without materially increasing tablet mass. This is commercially important where formulations must meet weight variation, content uniformity, disintegration, and dissolution requirements.

Direct compression and continuous manufacturing

Direct compression reduces granulation steps and can lower production costs. It also increases sensitivity to powder flow, segregation, and blend uniformity. Colloidal silicon dioxide can improve the handling characteristics of blends used in direct-compression processes.

Continuous manufacturing creates a similar demand driver. Stable powder flow and predictable residence time are important for process control, although the excipient does not eliminate the need for formulation-specific process development.

Growth in nutraceuticals and consumer health

Nutraceutical tablets, capsules, powders, and premixes use silicon dioxide as an anti-caking and flow aid. This sector expands the addressable market but is generally more price-sensitive and less qualification-intensive than regulated pharmaceutical applications.

Formulation of difficult powders

Colloidal silicon dioxide can adsorb liquids and oils, supporting the conversion of liquid active ingredients, flavors, or botanical extracts into processable powders. Its use is relevant to formulations with hygroscopic or cohesive materials.

Which companies supply pharmaceutical-grade colloidal silicon dioxide?

The market includes large integrated silica producers, specialty excipient suppliers, and regional distributors. Important commercial brands and suppliers include the following:

Company	Relevant product or platform	Commercial position
Evonik Industries	AEROSIL pharmaceutical grades, including AEROSIL 200 Pharma	Global specialty silica supplier with pharmaceutical technical support
Cabot Corporation	CAB-O-SIL pharmaceutical and specialty grades	Global fumed silica producer with broad industrial infrastructure
Wacker Chemie	HDK pharmaceutical and specialty silica grades	Integrated silicone and pyrogenic silica manufacturer
Tokuyama	Pharmaceutical and specialty silica products	Strong position in Asian and international markets
Fuji Silysia Chemical	Synthetic silica and pharmaceutical excipient products	Specialty silica and adsorbent applications
Grace	Silica-based pharmaceutical and formulation materials	Broader excipient and drug-delivery portfolio
Regional producers	Multiple pharmaceutical and food-grade silica products	Compete on price, availability, and local regulatory support

Product names and exact grade availability vary by jurisdiction. Pharmaceutical customers typically evaluate specific surface area, primary particle size, aggregate structure, moisture, pH, bulk density, tapped density, microbial quality, elemental impurities, and powder-flow performance.

How does colloidal silicon dioxide compare with competing excipients?

Colloidal silicon dioxide competes with other flow aids and formulation technologies rather than with one direct substitute.

Excipient or technology	Relative advantage	Limitation
Colloidal silicon dioxide	Strong flow improvement at low use levels	Can increase dust, affect dissolution, and vary by grade
Magnesium stearate	Effective lubricant and widely used	Excessive use can reduce tablet hardness or slow dissolution
Talc	Lubricating and anti-adherent properties	Regulatory and formulation preferences vary
Starch derivatives	Multifunctional filler and disintegrant properties	Often requires higher use levels
Calcium silicate	Strong adsorption and flow performance	Different compaction and dissolution behavior
Granulation	Improves flow and compressibility	Adds equipment, energy, and process steps
Co-processed excipients	Can provide optimized flow and compression	Higher formulation cost and supplier dependence

The principal competitive advantage of colloidal silicon dioxide is low-dose functionality. Its main commercial weakness is that many formulations can be redesigned using granulation, alternative glidants, or co-processed excipients.

What regulatory status applies to colloidal silicon dioxide?

Colloidal silicon dioxide is an established excipient rather than a new active pharmaceutical ingredient. Regulatory review focuses on material identity, grade, impurity profile, manufacturing controls, intended use, and formulation-specific safety.

United States

The FDA Inactive Ingredient Database provides precedent for silicon dioxide use in approved drug products. Presence in the database does not create a universal authorization for every dosage form, route, concentration, or product. Sponsors must establish suitability in the relevant formulation and comply with current good manufacturing practice requirements.

Colloidal silicon dioxide is generally supported through compendial standards, supplier documentation, drug-master-file information where available, and formulation-specific development data.

European Union

European drug manufacturers rely on European Pharmacopoeia standards and excipient risk-management expectations. The European Medicines Agency requires applicants to describe excipient quality, safety, manufacturing, and control information in the marketing-authorization dossier.

Food and nutraceutical use

Silicon dioxide is authorized as food additive E551 in the European Union under applicable specifications. EFSA has reviewed the safety assessment of silicon dioxide and E551, including particle-size and nanomaterial-related considerations (European Food Safety Authority, 2018). Food authorization does not replace pharmaceutical qualification.

What patents protect colloidal silicon dioxide?

No major Orange Book patent estate protects colloidal silicon dioxide as a pharmaceutical excipient. The material is an established inorganic substance, and its commercial protection is based primarily on manufacturing know-how, grade consistency, regulatory documentation, and customer qualification.

Patent activity can still arise around:

• Surface-treated silica.
• Porous or mesoporous silica.
• Drug-delivery particles.
• Silica-containing adsorbents.
• Co-processed excipients.
• Specialized powder-flow systems.
• Formulations using silica to improve dissolution or stability.
• Manufacturing processes that control morphology or surface chemistry.

These rights generally protect a specific composition, process, particle structure, or formulation. They do not normally prevent use of standard compendial colloidal silicon dioxide in conventional tablets or capsules.

When does colloidal silicon dioxide lose exclusivity?

Colloidal silicon dioxide has no conventional pharmaceutical exclusivity period comparable to a new chemical entity. It does not receive NCE exclusivity, pediatric exclusivity, or an Orange Book patent term because it is an excipient rather than an approved active drug.

Commercial exclusivity is instead created by:

1. Customer qualification.
2. Supplier audits.
3. Drug-master-file support.
4. Proprietary grade specifications.
5. Validated manufacturing processes.
6. Regulatory change-control history.
7. Reliable supply during shortages or disruptions.

A pharmaceutical company can often qualify an alternative supplier, but the change may require comparability testing, process validation, stability assessment, and regulatory documentation. That creates practical switching costs without creating legal exclusivity.

Are there Paragraph IV challenges or biosimilar risks?

Paragraph IV litigation does not normally apply to colloidal silicon dioxide itself. Paragraph IV certifications concern patents listed in the FDA Orange Book for approved drug products. An excipient supplier could become involved in litigation if a drug formulation patent allegedly covers a particular use or composition containing silica, but that would be a drug-product dispute rather than an excipient exclusivity challenge.

Biosimilar risk is also limited. Colloidal silicon dioxide is used mainly in small-molecule oral solid-dose products. Biologics and biosimilars use different formulation systems, including buffers, stabilizers, surfactants, sugars, amino acids, and injectable-grade excipients. Some silica-based materials may be relevant to purification or delivery technologies, but standard colloidal silicon dioxide is not a core biosimilar excipient.

What manufacturing and intellectual-property barriers affect the market?

The key manufacturing barrier is reproducibility. Commercial value depends on controlling:

• Particle-size distribution.
• Surface area.
• Moisture and loss on drying.
• Silanol-group chemistry.
• Bulk and tapped density.
• Aggregate structure.
• Trace metals and elemental impurities.
• Microbial quality.
• Packaging and dust control.

Pyrogenic silica production requires high-temperature processing and specialized equipment. Energy consumption, gas costs, environmental controls, and plant utilization can affect margins. Pharmaceutical grades require additional segregation, documentation, testing, and change-control systems.

Intellectual property is less important than manufacturing know-how. Patents may protect specific processes or surface modifications, but the largest barrier to entry is achieving repeatable pharmaceutical performance at scale and maintaining an acceptable regulatory history.

How strong is the patent estate for colloidal silicon dioxide?

The standard excipient patent estate is weak from an exclusivity perspective and moderate from a technology perspective.

IP category	Strength
Standard colloidal silicon dioxide composition	Low
Pharmaceutical-grade purification and controls	Moderate, mainly know-how
Surface-modified silica	Moderate to strong for specific claims
Mesoporous or drug-delivery silica	Stronger, depending on claims and jurisdiction
Formulation-specific use patents	Variable
Manufacturing process patents	Variable
Supplier regulatory files and qualification history	Commercially important but not patent exclusivity

The most defensible commercial positions are differentiated pharmaceutical grades, validated performance data, and supply-chain reliability.

What is the financial trajectory for colloidal silicon dioxide suppliers?

The financial outlook is positive but constrained by the product’s commodity characteristics.

Revenue trajectory

Revenue should rise with pharmaceutical production, generic volume, nutraceutical consumption, and demand for higher-performance excipients. Growth is likely to be more resilient in regulated pharmaceutical grades than in industrial applications because pharmaceutical customers prioritize continuity and quality over the lowest nominal price.

Margin trajectory

Margins are influenced by:

• Energy and raw-material costs.
• Plant utilization.
• Product mix between industrial and pharmaceutical grades.
• Qualification-driven customer retention.
• Freight and packaging costs.
• Regional pricing pressure.
• Regulatory compliance costs.

Pharmaceutical grades can command a premium over standard industrial material, but the premium is limited by the low cost of the excipient in the finished product and the availability of alternative suppliers.

Capital allocation

Suppliers with integrated silica production can spread fixed costs across multiple end markets. This supports resilience but exposes earnings to cyclicality in construction, automotive, coatings, electronics, and chemicals. Companies with large industrial portfolios do not generally report colloidal silicon dioxide revenue separately, making product-level valuation difficult.

The most attractive commercial strategy is usually portfolio-based: sell standard silica grades at scale, then capture higher margins through pharmaceutical grades, technical services, regulatory support, and specialized silica products.

What generic launch risks exist for products using colloidal silicon dioxide?

Generic entry is unlikely to be blocked by the excipient itself. The principal risks are formulation and manufacturing risks:

• A substitute supplier may produce different flow characteristics.
• Grade changes may affect dissolution or content uniformity.
• Higher or lower surface area may alter lubricant distribution.
• Moisture differences may affect stability.
• Silica may interact with sensitive active ingredients or excipients.
• A formulation patent may claim a specific silica-containing composition.
• Regulatory agencies may require bridging data after a supplier change.

For originator and generic manufacturers, the best protection is not excipient exclusivity. It is control of the finished formulation, process parameters, analytical methods, and regulatory change history.

What geographic markets are most important?

North America and Europe remain high-value markets because of strict documentation, established compendial practice, and extensive generic manufacturing. Asia-Pacific is the main volume-growth region, supported by pharmaceutical production in India and China and expanding local excipient capacity.

Regional dynamics include:

• India: strong generic manufacturing base and price-sensitive procurement.
• China: expanding domestic pharmaceutical and excipient production, with variable supplier qualification standards.
• Europe: strong demand for compendial compliance and supply-chain documentation.
• United States: significant generic and contract manufacturing demand, with FDA database precedent important to formulation development.
• Japan and South Korea: sophisticated quality systems and specialized pharmaceutical manufacturing.

Local production can reduce freight exposure, but global drug companies often retain dual sourcing to manage shortages, geopolitical risk, and plant disruptions.

What litigation and settlement agreements affect the market?

No broad market-wide litigation or settlement framework governs standard colloidal silicon dioxide. Disputes are more likely to involve:

• Product specifications.
• Contamination or out-of-specification batches.
• Supply contracts.
• Confidential manufacturing information.
• Formulation patents.
• Drug-device or drug-delivery systems containing silica.

Settlement agreements are generally confidential and product-specific. They do not create a market-wide restriction on standard pharmaceutical colloidal silicon dioxide.

Key Takeaways

• Colloidal silicon dioxide is a mature, essential processing excipient for tablets, capsules, powders, and selected suspension systems.
• Pharmaceutical demand is linked to oral solid-dose production, generic medicines, direct compression, and nutraceutical manufacturing.
• Evonik, Cabot, Wacker, Tokuyama, Fuji Silysia, Grace, and regional producers compete through grade performance and regulatory support.
• No conventional Orange Book, Paragraph IV, or biosimilar exclusivity protects the standard excipient.
• Manufacturing know-how, particle control, pharmaceutical documentation, and customer qualification create the main commercial barriers.
• Revenue growth should be steady, but margins remain exposed to energy costs, industrial-cycle weakness, and generic-drug pricing pressure.
• The strongest long-term opportunities are pharmaceutical-grade differentiation, specialty silica, co-processed excipients, and formulation-support services.
• Product-level financial data is limited because major suppliers report colloidal silicon dioxide within broader silica or health-care segments.

FAQs

Is colloidal silicon dioxide the same as silica gel?

No. Colloidal silicon dioxide is generally a finely divided amorphous silica used as a flow aid or adsorbent. Silica gel is a porous, hydrated form of silica with different morphology and performance characteristics.

Can pharmaceutical manufacturers change colloidal silicon dioxide suppliers?

Yes, but the change may require comparability testing, process assessment, stability review, supplier qualification, and regulatory documentation. The required work depends on the dosage form and the supplier-grade differences.

Does colloidal silicon dioxide affect tablet dissolution?

It can. The effect depends on grade, surface area, concentration, mixing order, lubricant level, and interaction with the active ingredient. Excessive or poorly dispersed silica may alter wetting, disintegration, or dissolution.

Is colloidal silicon dioxide considered a nanomaterial?

Some commercial materials contain primary particles in the nanoscale range, although the marketed powder may consist of larger aggregates and agglomerates. Regulatory treatment depends on jurisdiction, particle characterization, intended use, and applicable nanomaterial definitions.

Is pharmaceutical-grade colloidal silicon dioxide vulnerable to supply shortages?

Yes. Risk can arise from plant outages, energy constraints, transport disruption, qualification bottlenecks, or regional dependence on a small number of approved grades. Dual sourcing reduces risk but can require substantial comparability work.

References

1. European Food Safety Authority. (2018). Re-evaluation of silicon dioxide (E551) as a food additive. EFSA Journal, 16(1), 5088. https://doi.org/10.2903/j.efsa.2018.5088

2. European Medicines Agency. (2015). Guideline on the quality of water for pharmaceutical use. European Medicines Agency. https://www.ema.europa.eu

3. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe. https://www.edqm.eu

4. U.S. Food and Drug Administration. (n.d.-a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Food and Drug Administration. (n.d.-b). Current good manufacturing practice for drugs. https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations

6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention. https://www.usp.org

7. IPEC Federation. (2017). The IPEC excipient information package: Excipient composition, quality, regulatory and safety information. International Pharmaceutical Excipients Council. https://ipec-federation.org